Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

被引：0
|
作者：
Jung, Sung-Hoon [1 ]
Lee, Je-Jung [2 ]
Kim, Mihee [3 ]
Min, Chang-Ki [4 ]
Lee, Ji Yun [5 ]
Jo, Jae-Cheol [6 ]
Yoon, Sung-Soo [7 ]
Lim, Sung-Nam [8 ]
Do, Young Rok [9 ]
Kim, Kihyun [10 ]
Lee, Jae Hoon [11 ]
Yoo, Kwai Han [11 ]
Bae, Sung Hwa [12 ]
Yi, Jun Ho [13 ]
Jung, Jongheon [14 ]
Eom, Hyeon-Seok [15 ]
机构：
[1] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Sch Med, Hwasun, South Korea
[2] Kyungpook Natl Univ, Dept Hematol Oncol, Sch Med, Kyungpook Natl Univ Hosp, Daegu, South Korea
[3] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea
[4] Seoul St Marys Hosp, Seoul, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[6] Ulsan Univ Hosp, Ulsan, South Korea
[7] Seoul Natl Univ, Coll Med, Seoul, South Korea
[8] Inje Univ, Coll Med, Haeundae Paik Hosp, Busan, South Korea
[9] Keimyung Univ, Dept Hematooncol, Dongsan Med Ctr, Daegu, South Korea
[10] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[11] Gachon Univ, Gil Med Ctr, Seongnam, South Korea
[12] Daegu Catholic Univ Hosp, Daegu, South Korea
[13] Chung Ang Univ Hosp, Seoul, South Korea
[14] Natl Canc Ctr, Goyang, South Korea
[15] Natl Canc Ctr Korea, Dept Internal Med, Goyang, South Korea
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-144
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [1] Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)
    Kim, Mihee
    Lee, Je-Jung
    Min, Chang-Ki
    Lee, Ji Yun
    Jo, Jae-Cheol
    Yoon, Sung-Soo
    Lim, Sung-Nam
    Do, Young Rok
    Kim, Kihyun
    Lee, Jae Hoon
    Yoo, Kwai Han
    Bae, Sung Hwa
    Yi, Jun Ho
    Jung, Jongheon
    Eom, Hyeon-Seok
    Jung, Sung-Hoon
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2233 - 2240
  • [2] Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)
    Mihee Kim
    Je-Jung Lee
    Chang-Ki Min
    Ji Yun Lee
    Jae-Cheol Jo
    Sung-Soo Yoon
    Sung-Nam Lim
    Young Rok Do
    Kihyun Kim
    Jae Hoon Lee
    Kwai Han Yoo
    Sung Hwa Bae
    Jun Ho Yi
    Jongheon Jung
    Hyeon-Seok Eom
    Sung-Hoon Jung
    Annals of Hematology, 2023, 102 : 2233 - 2240
  • [3] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263
  • [4] Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Smith, Scott E.
    Sterrenberg, Danielle
    Vesole, David H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1391 - 1396
  • [5] Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
    Byun, Ja Min
    Lee, Jayoun
    Shin, Sang-Jin
    Kang, Minjoo
    Yoon, Sung-Soo
    Koh, Youngil
    BLOOD RESEARCH, 2018, 53 (02) : 105 - 109
  • [6] BUSULFAN PLUS CYCLOPHOSPHAMIDE AND ETOPOSIDE VERSUS HIGH-DOSE MELPHALAN AS CONDITIONING IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
    Park, Seonyang
    Lee, Youngjoon
    Lim, Sungnam
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 484 - 484
  • [7] Busulfan plus cyclophosphamide and etoposide versus high-dose melphalan as conditioning in autologous stem cell transplantation for newly diagnosed multiple myeloma
    Lim, Sungnam
    Park, Seon Yang
    Lee, Yongjun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S153 - S153
  • [8] Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
    Aypar, Eda
    Izzettin, Fikret Vehbi
    Aki, Sahika Zeynep
    Sancar, Mesut
    Yegin, Zeynep Arzu
    Turkoz-Sucak, Gulsan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (04) : 281 - 289
  • [9] Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis
    Song, Ga-Young
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2714 - 2721
  • [10] High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma
    谷景立
    China Medical Abstracts (Internal Medicine), 2019, 36 (04) : 230 - 231
12345